StreetInsider.com News Articles

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:01:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June 2026.

The grants, in the form of Restricted Stock Units (RSUs), totaled 17,000 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The RSUs were granted on July 1,

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:01:00 -0400

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:01:00 -0400

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:01:00 -0400

Delcath doses first patient in breast cancer trial of Hepzato

Thu, 09 Jul 2026 08:00:15 -0400

Delcath Systems, Inc. (Nasdaq: DCTH) announced that the first patient has been dosed in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care treatment for liver-dominant metastatic breast cancer. The dosing took place at the European Institute of Oncology in Milan, Italy.

The trial, known as DELUMA (NCT06875128), will evaluate the safety and efficacy of HEPZATO combined with standard of care versus standard of care alone in patients with liver-dominant HER2-negative metastatic breast cancer following the failure of previous treatments. Physician-selected standard of care options include eribulin, vinorelbine, or capecitabine.

The randomized, controlled trial plans to enroll

Delcath doses first patient in breast cancer trial of Hepzato

Thu, 09 Jul 2026 08:00:15 -0400

The randomized, controlled trial plans to enroll

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Thu, 09 Jul 2026 08:00:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care (SOC) treatment for liver-dominant metastatic breast cancer (mBC).

The Phase 2 trial (DELUMA; NCT06875128) will evaluate the safety and efficacy of HEPZATO in combination with standard of care (SOC) versus SOC alone in patients with liver-dominant HER2-negative mBC following the failure of

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Thu, 09 Jul 2026 08:00:00 -0400

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Thu, 09 Jul 2026 08:00:00 -0400

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Thu, 09 Jul 2026 08:00:00 -0400

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts